This report was first published by Endpoints News. To see the original version, click here
Novartis will spend $2 billion upfront to buy a more selective PI3Kα inhibitor, intensifying the competition to develop a new wave of breast cancer drugs with fewer side effects.
The Swiss pharma already markets the PI3Kα-targeting breast cancer drug Piqray, but it comes with a high rate of hyperglycemia and diarrhea, making combination approaches challenging. To address these side effects, Novartis and other drugmakers are now homing in on “mutant-selective” inhibitors that do not target the wild-type PI3Kα enzyme.
您已阅读18%（610字），剩余82%（2796字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。